Kb): (616

: For those who stopped the medication, the median time until they did so was only 7 months .

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months. (616 KB)

The study highlighted a few differences between "real-world" patients and those in trials: : For those who stopped the medication, the

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications the medical community should focus on:

The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on: